Abstract

BackgroundThe prognostic significance of ABO blood type for lymphoma is largely unknown. We evaluated the prognostic role of ABO blood type in patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL).MethodsWe retrospectively analyzed clinical data of 697 patients with newly diagnosed ENKTL from three cancer centers. The prognostic value of ABO blood type was evaluated using Kaplan–Meier curves and Cox proportional hazard models. The prognostic values of the International Prognostic Index (IPI) and the Korean Prognostic Index (KPI) were also evaluated.ResultsCompared with patients with blood type O, those with blood type non-O tended to display elevated baseline serum C-reactive protein levels (P = 0.038), lower rate of complete remission (P = 0.005), shorter progression-free survival (PFS, P < 0.001), and shorter overall survival (OS, P = 0.001). Patients with blood type O/AB had longer PFS (P < 0.001) and OS (P = 0.001) compared with those with blood type A/B. Multivariate analysis demonstrated that age >60 years (P < 0.001), mass ≥5 cm (P = 0.001), stage III/IV (P < 0.001), elevated serum lactate dehydrogenase (LDH) levels (P = 0.001), and blood type non-O were independent adverse predictors of OS (P = 0.001). ABO blood type was found to be superior to both the IPI in discriminating patients with different outcomes in the IPI low-risk group and the KPI in distinguishing between the intermediate-to-low- and high-to-intermediate-risk groups.ConclusionsABO blood type was an independent predictor of clinical outcome for patients with ENKTL.

Highlights

  • The prognostic significance of ABO blood type for lymphoma is largely unknown

  • The baseline C-reactive protein (CRP) levels were available in 228 patients, and the baseline plasma Epstein–Barr virus (EBV)-DNA data were available in 171 patients

  • Li et al [24] evaluated the prognostic role of ABO blood type in 1601 patients with curatively resected non-small cell lung cancer (NSCLC), and they found that patients with blood type O or B had significantly prolonged overall survival (OS) and disease-free survival (DFS) compared with those with blood type A or AB

Read more

Summary

Introduction

We evaluated the prognostic role of ABO blood type in patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL). Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct subtype of non-Hodgkin’s lymphoma (NHL) with unique clinicopathologic characteristics and geographic distribution [1]. ENKTL accounts for 11% of all NHL cases in Chinese populations [3] and accounts for 5%–10% of all NHL cases in the populations of Asia and Central/South America [2, 4]. The application of l-asparaginase-containing chemotherapy significantly improves the outcomes of ENKTL patients with 5-year OS rate ranging from 50% to 86.9% [6, 10,11,12,13].

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call